This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reesink-Peters, N. Articles by van der Zee, A. G.J. Search for Related Content PubMed PubMed Citation Articles by Reesink-Peters, N. Articles by van der Zee, A. G.J. Social Bookmarking                            What's this?

Preoperative Serum Squamous Cell Carcinoma Antigen Levels in Clinical Decision Making for Patients With Early-Stage Cervical Cancer

From the Departments of Gynecological Oncology, Pathology, Radiotherapy, Medical Oncology, and Epidemiology and Statistics, University Hospital Groningen; Department of Gynecological Oncology, University Hospital Amsterdam, Amsterdam; and Department of Obstetrics and Gynecology, Meander Medical Centre, Amersfoort, The Netherlands.

Address reprint requests to A.G.J. van der Zee, MD, PhD, Department of Gynecological Oncology, University Hospital Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands; e-mail: a.g.j.van.der.zee{at}og.umog.nl

PURPOSE: To prevent morbidity associated with double modality treatment, early-stage cervical cancer patients should only be offered surgery when there is a low likelihood for adjuvant radiotherapy. We analyzed whether serum squamous cell carcinoma antigen (SCC-ag) analysis allows better preoperative identification of patients with a low likelihood for adjuvant radiotherapy than currently used clinical parameters.

PATIENTS AND METHODS: In a cohort study, International Federation of Gynecology and Obstetrics (FIGO) stage, tumor size, and preoperative serum SCC-ag levels, as determined by enzyme immunoassay, were related to the frequency of postoperative indications for adjuvant radiotherapy in 337 surgically treated, FIGO stage IB/IIA, squamous cell cervical cancer patients.

RESULTS: In patients with normal preoperative SCC-ag, 16% of IB1 and 29% of IB2/IIA had postoperative indications for adjuvant radiotherapy, in contrast to 57% of IB1 and 74% of IB2/IIA patients with elevated (> 1.9 ng/mL) serum SCC-ag (P < .001). Serum SCC-ag was the only independent predictor for a postoperative indication for radiotherapy (odds ratio, 7.1; P < .001). Furthermore, in IB1 patients that did not have indications for adjuvant radiotherapy, 15% of patients with elevated preoperative serum SCC-ag levels recurred within 2 years, compared with 1.6% of patients with normal serum SCC-ag levels (P = .02).

CONCLUSION: In early-stage cervical cancer, determination of serum SCC-ag levels allows more refined preoperative estimation of the likelihood for adjuvant radiotherapy than current clinical parameters, and simultaneously identifies patients at high risk for recurrence when treated with surgery only. The role of preoperative serum SCC-ag in the management of patients with early-stage cervical cancer deserves further investigation.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S.-W. Kim, K. Cheon, C.-H. Kim, J.-H. Yoon, D. H. Hawke, R. Kobayashi, L. Prudkin, I. I. Wistuba, R. Lotan, W. K. Hong, et al. Proteomics-Based Identification of Proteins Secreted in Apical Surface Fluid of Squamous Metaplastic Human Tracheobronchial Epithelial Cells Cultured by Three-Dimensional Organotypic Air-Liquid Interface Method Cancer Res., July 15, 2007; 67(14): 6565 - 6573. [Abstract] [Full Text] [PDF]